Send the following on WhatsApp
Continue to Chat日本醫藥產業亮點: 核准 Dexamethasone 為 COVID-19 的二線治療、Teva 拓展學名藥市場 https://geneonline.news/asia-pharma-news-japan/?variant=zh-cn
日本醫藥產業亮點: 核准 Dexamethasone 為 COVID-19 的二線治療、Teva 拓展學名藥市場 https://geneonline.news/asia-pharma-news-japan/?variant=zh-cn